Low plasma concentrations achieved with conventional schedules administration of ganciclovir in patients with AIDS

被引:18
作者
Piketty, C
Bardin, C
Gilquin, J
Mahe, V
Kazatchkine, MD
Chast, F
机构
[1] HOP BROUSSAIS,INSERM,U430,F-75014 PARIS,FRANCE
[2] HOP HOTEL DIEU,SERV PHARM PHARMACOL,PARIS,FRANCE
关键词
D O I
10.1093/infdis/174.1.188
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasma concentration of ganciclovir was studied prospectively in 15 AIDS patients treated for acute cytomegalovirus (CMV) retinitis. Ganciclovir was administered at a mean dose of 10.3 +/- 0.6 mg/kg/day. The mean trough plasma concentration was 0.6 +/- 0.3 mg/L (n = 24), and the mean peak concentration was 7.2 +/- 2.4 mg/L (n = 6). In 12 patients, trough concentrations were below the range that has been associated with effective treatment. Low trough concentrations were associated with treatment failure in 6 patients. Following an increase in the daily dose, improvement was observed in 4 of the 6 patients. These results suggest that low plasma ganciclovir levels are associated with the failure of therapy, Monitoring the plasma concentration of ganciclovir may thus be useful before considering the virus to be resistant to the drug or before switching from ganciclovir to foscarnet.
引用
收藏
页码:188 / 190
页数:3
相关论文
共 15 条
[1]  
BARDIN C, 1993, 22 EUR S CLIN PHARM, P114
[2]  
BUHLES WC, 1988, REV INFECT DIS S3, V10, P495
[3]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[4]  
ERDMAN SM, 1994, 34 INT C ANT AG CHEM
[5]   GANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED HOSTS [J].
ERICE, A ;
JORDAN, C ;
CHACE, BA ;
FLETCHER, C ;
CHINNOCK, BJ ;
BALFOUR, HH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (22) :3082-3087
[6]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[7]   GANCICLOVIR - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CYTOMEGALOVIRUS INFECTIONS [J].
FAULDS, D ;
HEEL, RC .
DRUGS, 1990, 39 (04) :597-638
[8]   HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG [J].
FLETCHER, C ;
SAWCHUK, R ;
CHINNOCK, B ;
DEMIRANDA, P ;
BALFOUR, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) :281-286
[9]  
FLETCHER C V, 1991, Pharmacotherapy, V11, P277
[10]   FOSCARNET THERAPY FOR GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS [J].
JACOBSON, MA ;
DREW, WL ;
FEINBERG, J ;
ODONNELL, JJ ;
WHITMORE, PV ;
MINER, RD ;
PARENTI, D .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1348-1351